Shanghai Mingju Biotechnology

Shanghai Mingju Biotechnology is a biopharmaceutical company based in Shanghai, China, and a key operating subsidiary of JW Therapeutics. The company specializes in the development, manufacturing, and commercialization of innovative cell-based immunotherapies, particularly Chimeric Antigen Receptor T-cell (CAR-T) therapies. Its lead product, relmacabtagene autoleucel (Relma-cel), was the first CAR-T therapy to be approved as a Category 1 biologics product in China for relapsed or refractory large B-cell lymphoma. Shanghai Mingju maintains state-of-the-art GMP manufacturing facilities and R&D operations to support a robust pipeline targeting various hematologic malignancies and solid tumors.